BioCentury
ARTICLE | Financial News

CymaBay to raise $30 million, move to NASDAQ

April 10, 2014 12:05 AM UTC

CymaBay Therapeutics Inc. (OTCQB:CYMA) said it plans to raise up to $30 million in a follow-on and move its listing to NASDAQ. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. CymaBay (formerly Metabolex Inc.) became a publicly reporting company via the Form 10 pathway in October and began trading on the OTCQB in January. CymaBay's arhalofenate ( MBX-102) is in a Phase IIb trial to treat gout, with data expected in 1H15. The compound is a uricosuric agent. ...